From the aCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada
bDepartment of Epidemiology and Biostatistics, and of Medicine, McGill University, Montreal, Canada
cDepartment of Neurology and Neurosurgery, McGill University, Montreal, Canada.
Submitted August 16, 2022; accepted May 8, 2023
This work is not funded. Samy Suissa is the recipient of the Distinguished James McGill Professorship award. Data access was available thanks to infrastructure funding from the Canadian Institutes of Health Research (CIHR) and the Canadian Foundation for Innovation (CFI).
S.S. attended scientific advisory committee meetings for Atara, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Seqirus, and received speaking fees from Boehringer-Ingelheim and Novartis. The other authors have no conflicts to report.
This study is based in part on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare Products Regulatory Agency. The data are provided by patients and collected by the UK National Health Service as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. Because electronic health records are classified as “sensitive data” by the UK Data Protection Act, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition. The primary care data can be requested via application to the Clinical Practice Research Datalink (https://www.cprd.com).
Supplemental digital content is available through direct URL citations in the HTML and PDF versions of this article (www.epidem.com).
Correspondence: Samy Suissa, Centre for Clinical Epidemiology, Jewish General Hospital, 3755 Cote Ste-Catherine, Montreal, Québec, H3T 1E2, Canada. E-mail: [email protected].
